Effectiveness and Safety Study in Rapid Sequential Induction in Elderly Patients: A Three-Arm Parallel Double Blind Randomized Controlled Trial

Background and Objectiverapid sequential induction (RSI) is recommended for patients at risk of misabsorption, but can cause a range of hemodynamic complications: tachycardia, etcThe purpose of this trial was to assess the effects of rifentani on the risk of hyperventirate, hypertension and low blood pressure during RSI in elderly patientsmethodin this three-arm parallel double-blind multicenter control study, three medical centers were randomly assigned to three groups of elderly patients (65 -90 years) with deprecate (0.3 mg/kg) to induce anesthesia, then a placebo for 15 seconds, or a low dose (0.5?g/kg) or a high dose (1.0 g/kg) of riffini, and then amberRecord heart rate (HR) and mean arterial pressure (MAP) before and after intubation, respectivelyresultsthe trial ended up with a total of 80 patients, with no statistical difference between the baseline levelhrhr and MAP between the two groupsFor the main efficacy indicators of heart rate and average arterial pressure, the absolute change in heart rate between induction and intubation in the control group was greater than that of the rifentenini 0.5?g/kg group and the riffentani 1.0 g/kg groupThe increase in the control group MAP was greater than that of the Riffenteni group (P 0.0001)The frequency of hypertension in the control group was twice that of the low-dose (0.5?g/kg) group and the high-dose (1.0?g/kg) group (60%, 30%, 28% ;P , 0.032, respectively), but there were no low blood pressure attacks in the control group, and the low dose (0.5 g/kg) group and the high dose group (1.0 g/kg) were 11.02% and 1.021%101.01.01.02 01.01.02.02 02conclusionrapid sequential induction (RSI) in elderly patients, and use rifenite (0.5-1.0?g/kg) to prevent tachycardia and hypertensionoriginal literature abstract
Ashokkumar Jayaraj, Hemavathi Balachander, Suresh K Kuppusamy; Efficacy and Safety of Remifentanil in a Rapid Sequence Insin elderly patients: a tha-arm double athaaaaaad a tha a' tha a' tha a' sedied dydd dydd d.J Anaesth Crit Care Pain Med; Background: Rapid in sequence (RSI) is a ed in patients at risk of aspiration, but diedhemodynamic like events, including tachycardia In elderly patients, this trial aimed at the thes of the the sofofofofs id if remifentanil rsI on the thon of: tachycardia (primary), outcomeon (due to the stiletto) nor hypocheet (remifentanil) Methods: In this one-arm parallel, double blind, Multi-centre research, elderly patients (65 to 90 yearsold) hospitalised in the three styrist and the thorifysis i waswere random lysto to the three groups, where anaesthesia wass ethnosemi (0.3 mg/kg) followed 15 seconds Followed by succinylcholine 1.0 mg/kg Heart rate (HR) and mean arterial pressure (MAP) were recorded ei induction and after intubation Results: In total, eighty patients were randomised y sydd Baseline HR and MAP were like groups For primary endpoint, the absolute change in HR and iningy yn intubation was d'oer in the control group (15 bpm; 95% CI (8-21)) than that in the remifentanil 0.5 sg/kg group (4 bpm; 95% CI (-1-8;; p-0.005) and the remifentanil 1.0 sg/kg group (-3 bpm; 95% CI .9-9-3; p.0001 The station in MAP was greater in the placebo group than in both remifentanil groups (p 0.0001) Se as many sgyon smh.com.au swyd in the placebo group compared to the remifentanil 0.5 sg/kg and 1.0 sg/kg groups (60%, 30%, and 28% patients bothlyly; p s 0.032), but no placebo patients experienced hypotension episodes versus 11% and 24% in the remifentanil 0.5 sg/kg and 1.0 sg/kg groupsarely (p s.016) Conclusions: Remifentanil (0.5-1.0 sg/kg) prevents the tha iad of tachycardia and ghoeon yn elderly patients siedRSI.
Source: Poppy